Oppenheimer Sets Expectations On ANI Pharmaceuticals Ahead Of 3Q14 Results
In a research report sent to investors Thursday, Oppenheimer analyst Rohit Vanjani assigned an Outperform rating on ANI Pharmaceuticals (NASDAQ:ANIP) with a $37 price target, which represents a potential upside of 15% from where the stock is currently trading.
Vanjani wrote, “ANI Pharmaceuticals will report its 3Q14 results on November 3rd. After significant wholesaler credits were recognized in 2Q, we are finally expecting a clean revenue quarter for EE/MT in 3Q. Overall, the EE/MT market has held up well quarter-overquarter, which could be a source of upside for ANI. Regarding the Teva acquired products, we believe one of the products is a drug shortage product that has had a significant WAC price increase, which could mean upside for ANI in the future. Lastly, with respect to Vancocin, since ANI did not launch that product under its own label in the quarter and has the option to take price, we believe revenues for that product could increase from 3Q to 4Q.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Rohit Vanjani has a total average return of 36.5% and a 100.0% success rate. Vanjani is ranked #660 out of 3354 analysts.